(Q44454375)

English

Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels

scientific article published in June 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

mixed hyperlipidemia

1 reference

based on heuristic

inferred from title

author name string

David M Capuzzi

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

John M Morgan

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Robert J Weiss

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Rohini R Chitra

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Howard G Hutchinson

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Michael D Cressman

6

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

language of work or name

0 references

publication date

1 June 2003

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

American Journal of Cardiology

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

91

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1304-1310

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900318-7

7 January 2021

Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900318-7

7 January 2021

Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900318-7

7 January 2021

Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900318-7

7 January 2021

Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900318-7

7 January 2021

Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900318-7

7 January 2021

Efficacy and safety of an extended-release niacin (Niaspan): a long-term study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900318-7

7 January 2021

Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900318-7

7 January 2021

Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900318-7

7 January 2021

The Eating Pattern Assessment Tool: a simple instrument for assessing dietary fat and cholesterol intake

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900318-7

7 January 2021

Niacin dosing: relationship to benefits and adverse effects

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900318-7

7 January 2021

Evaluating niacin in its various forms.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900318-7

7 January 2021

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900318-7

7 January 2021

Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900318-7

7 January 2021

Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900318-7

7 January 2021

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900318-7

7 January 2021

Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900318-7

7 January 2021

Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900318-7

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900318-7

7 January 2021

Identifiers

10.1016/S0002-9149(03)00318-7

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44454375&oldid=2024696784"